Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig

Part of paid clinical trials in Fort Myers, Florida.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07636863
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will review medical records of adults with cancer who received nivolumab either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection in community oncology clinics in the United States. The study will describe who receives each type of treatment, how the treatments are used, and selected safety events such as reactions at the injection or infusion site and infections.

Key Dates

Start date
Aug 21, 2025
Status verified
Jun 2026
Primary completion
Dec 22, 2025
Completion
Mar 27, 2026

Study Design

Enrollment
200 participants (actual)

Arms

  • Arm: IV Nivolumab
    Participants who receive intravenous (IV) nivolumab in community oncology settings.
  • Arm: SC Nivolumab + Hyaluronidase
    Participants who receive subcutaneous (SC) nivolumab combined with hyaluronidase

Primary Outcome Measure

Participant age [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Florida Cancer Specialists & Research InstituteFort MyersFlorida33916-

Find similar trials in Fort Myers, FL

By research site
Florida Cancer Specialists & Research Institute· Fort Myers, FL

Related Studies